Q32 Bio Inc (NASDAQ:QTTB) — Market Cap & Net Worth
Market Cap & Net Worth: Q32 Bio Inc (QTTB)
Q32 Bio Inc (NASDAQ:QTTB) has a market capitalization of $44.30 Million ($44.30 Million) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #22331 globally and #4704 in its home market, demonstrating a -22.22% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Q32 Bio Inc's stock price $5.04 by its total outstanding shares 12304352 (12.30 Million). Analyse Q32 Bio Inc (QTTB) cash flow conversion to see how efficiently the company converts income to cash.
Q32 Bio Inc Market Cap History: 2018 to 2026
Q32 Bio Inc's market capitalization history from 2018 to 2026. Data shows change from $4.95 Billion to $62.01 Million (-40.46% CAGR).
Index Memberships
Q32 Bio Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #642 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2143 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.00% | #249 of 263 |
Weight: Q32 Bio Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Q32 Bio Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Q32 Bio Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
-20.25x
Q32 Bio Inc's market cap is -20.25 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $4.95 Billion | $5.32 Million | -$55.58 Million | 930.53x | N/A |
| 2019 | $4.58 Billion | $1.67 Million | -$103.92 Million | 2751.86x | N/A |
| 2020 | $2.50 Billion | $2.70 Million | -$128.69 Million | 925.42x | N/A |
| 2021 | $806.18 Million | $33.97 Million | -$95.76 Million | 23.73x | N/A |
| 2022 | $279.06 Million | $6.65 Million | -$42.81 Million | 41.96x | N/A |
| 2023 | $134.66 Million | $-6.65 Million | -$53.74 Million | -20.25x | N/A |
Competitor Companies of QTTB by Market Capitalization
Companies near Q32 Bio Inc in the global market cap rankings as of May 2, 2026.
Key companies related to Q32 Bio Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Q32 Bio Inc Historical Marketcap From 2018 to 2026
Between 2018 and today, Q32 Bio Inc's market cap moved from $4.95 Billion to $ 62.01 Million, with a yearly change of -40.46%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $62.01 Million | +51.81% |
| 2025 | $40.85 Million | +2.79% |
| 2024 | $39.74 Million | -70.49% |
| 2023 | $134.66 Million | -51.75% |
| 2022 | $279.06 Million | -65.38% |
| 2021 | $806.18 Million | -67.76% |
| 2020 | $2.50 Billion | -45.46% |
| 2019 | $4.58 Billion | -7.42% |
| 2018 | $4.95 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Q32 Bio Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $44.30 Million USD |
| MoneyControl | $44.30 Million USD |
| MarketWatch | $44.30 Million USD |
| marketcap.company | $44.30 Million USD |
| Reuters | $44.30 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Q32 Bio Inc
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti"interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking … Read more